Loading...

PE anti-human CD8a Antibody

Pricing & Availability
Clone
RPA-T8 (See other available formats)
Regulatory Status
RUO
Workshop
IV T171
Other Names
T8, Leu2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
RPA-t8
Human peripheral blood lymphocytes stained with RPA-T8 PE
  • RPA-t8
    Human peripheral blood lymphocytes stained with RPA-T8 PE
  • RPA-T8_PE_CD8a_Antibody_042922
    Human peripheral blood was stained with CD8a (clone RPA-T8) PE (solid line) or mouse IgG1, κ PE isotype control (dashed line).

    Data was acquired on the Moxi Flow, exported, and processed using FlowJo software.
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
301007 25 tests £23
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301008 100 tests £50
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301064 100 µg £100
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301051 500 tests £223
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Pigtailed Macaque, Sooty Mangabey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
  5. Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
  6. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  7. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
Product Citations
  1. Penkava F, et al. 2020. Nat Commun. 3.76875. PubMed
  2. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  3. Wang T, et al. 2022. Front Immunol. 13:954121. PubMed
  4. Ellis GI, et al. 2022. Cell Rep Med. 3:100614. PubMed
  5. Zheng X, et al. 2022. Cells. 12: . PubMed
  6. Meyer S, et al. 2023. Cell Rep. 42:111995. PubMed
  7. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  8. Patskovsky Y, et al. 2023. Nat Commun. 14:3763. PubMed
  9. Zong D, et al. 2021. BMC Biol. 19:79. PubMed
  10. Ding L, et al. 2021. Cancers (Basel). 13:. PubMed
  11. Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed
  12. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  13. Lo Presti V, et al. 2021. Mol Ther Methods Clin Dev. 21:357. PubMed
  14. Schupp J, et al. 2021. Int J Mol Sci. 22:00. PubMed
  15. Theobald SJ, et al. 2022. EMBO Mol Med. 14:e15888. PubMed
  16. Mozhgani SH, et al. 2019. Retrovirology. 16:46. PubMed
  17. VanSaun M, et al. 2013. PLoS One. 8:73054. PubMed
  18. Mishra A, et al. 2021. Cell. 184(13):3394-3409.e20. PubMed
  19. Mohammadpour H, et al. 2021. Cell Rep. 37:109883. PubMed
  20. Calzoni E, et al. 2019. J Allergy Clin Immunol. 143:2317. PubMed
  21. Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed
  22. Reyes M, et al. 2021. Sci Transl Med. 13:. PubMed
  23. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  24. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
RRID
AB_2562056 (BioLegend Cat. No. 301007)
AB_2562056 (BioLegend Cat. No. 301008)
AB_2562056 (BioLegend Cat. No. 301064)
AB_2562056 (BioLegend Cat. No. 301051)

Antigen Details

Structure
Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
Distribution

Majority of thymocytes, T cell subset, NK cells

Function
MHC class I co-receptor, thymic differentiation, T cell activation
Ligand/Receptor
MHC Class I molecules
Cell Type
Dendritic cells, NK cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
925 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD8a RPA-T8 FC
APC/Cyanine7 anti-human CD8a RPA-T8 FC
Biotin anti-human CD8a RPA-T8 FC
FITC anti-human CD8a RPA-T8 FC
PE anti-human CD8a RPA-T8 FC
PE/Cyanine5 anti-human CD8a RPA-T8 FC
PE/Cyanine7 anti-human CD8a RPA-T8 FC
Purified anti-human CD8a RPA-T8 FC,CyTOF®,Costim,IHC
Alexa Fluor® 488 anti-human CD8a RPA-T8 FC
Alexa Fluor® 647 anti-human CD8a RPA-T8 FC
Pacific Blue™ anti-human CD8a RPA-T8 FC
Alexa Fluor® 700 anti-human CD8a RPA-T8 FC
PerCP anti-human CD8a RPA-T8 FC
PerCP/Cyanine5.5 anti-human CD8a RPA-T8 FC
Brilliant Violet 421™ anti-human CD8a RPA-T8 FC,ICC
Brilliant Violet 570™ anti-human CD8a RPA-T8 FC
Brilliant Violet 605™ anti-human CD8a RPA-T8 FC
Brilliant Violet 650™ anti-human CD8a RPA-T8 FC
Brilliant Violet 711™ anti-human CD8a RPA-T8 FC
Brilliant Violet 785™ anti-human CD8a RPA-T8 FC
Brilliant Violet 510™ anti-human CD8a RPA-T8 FC
Purified anti-human CD8a (Maxpar® Ready) RPA-T8 FC,CyTOF®
Alexa Fluor® 594 anti-human CD8a RPA-T8 ICC,FC
PE/Dazzle™ 594 anti-human CD8a RPA-T8 FC
APC/Fire™ 750 anti-human CD8a RPA-T8 FC
TotalSeq™-A0080 anti-human CD8a RPA-T8 PG
TotalSeq™-B0080 anti-human CD8a RPA-T8 PG
TotalSeq™-C0080 anti-human CD8a RPA-T8 PG
Ultra-LEAF™ Purified anti-human CD8a RPA-T8 FC,CyTOF®,Costim,IHC
Spark Violet™ 423 anti-human CD8a Antibody RPA-T8 FC
Spark Red™ 718 anti-human CD8a RPA-T8 FC
Spark PLUS UV395™ anti-human CD8a RPA-T8 FC
Go To Top Version: 4    Revision Date: 08/31/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account